Urogenital Neoplasms  >>  Halaven (eribulin mesylate)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Halaven (eribulin mesylate) / Eisai
NCT00278993 / 2005-004271-37: Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy

Completed
2
108
US
E7389
Eisai Inc.
Prostate Cancer
01/08
01/08

Download Options